Sise ME, Goldberg DS, Kort JJ, et al. - Given the reports of promising outcomes transplanting kidneys from donors with hepatitis C virus (HCV) infection into HCV-negative recipients from single-center trials and retrospective case series, researchers conducted this first multicenter trial with the aim to ascertain if those findings are generalizable. They assessed 30 HCV-uninfected adults who received a kidney from an HCV-viremic deceased donor and were cured of HCV with an 8-week regimen of coformulated glecaprevir and pibrentasvir initiated 2–5 days posttransplant. Acute cellular rejection developed in three patients and BK viremia near or > 10,000 copies/ml developed in three patients; immunosupression reduction led to resolution of these. Severe adverse events associated with the antiviral treatment or HCV were not observed. Overall excellent allograft function was noted at 6 months. Per these findings, HCV-viremic kidneys confer a valuable resource for transplantation and effective management of donor-derived HCV can be done with early antiviral treatment.